Statin use in pregnancy: No increased risk of birth defects

A recent research published in the JAMA Watch has examined the safety of using statins—medications commonly prescribed to lower cholesterol—during pregnancy, particularly during the first trimester. Historically, statins have been contraindicated during pregnancy due to concerns about potential risks to foetal development.

A comprehensive study analysed data from over 700,000 pregnancies and found no significant association between statin use in early pregnancy and the occurrence of major congenital malformations. This suggests that, for most women, taking statins during the first trimester does not increase the risk of birth defects.

However, the study did observe that exposure to high-intensity statins was linked to a slightly higher risk of congenital malformations. Additionally, while the overall risk of neurodevelopmental disorders in children appeared unaffected, there was a noted increase in low birth weight among those exposed to statins during pregnancy.

These findings provide reassurance for women who have been prescribed statins and are planning a pregnancy. Nonetheless, it is crucial for expectant mothers to consult with their healthcare providers before making any changes to their medication regimen. Individual health factors and the specific type of statin prescribed should be considered to ensure the safety of both mother and child.

In summary, while statins may not pose a significant risk for birth defects when used during early pregnancy, medical guidance is essential to make informed decisions about their use.